As lawsuits over permanent eye damage mount against GLP-1 drug manufacturers, legal claims focus on a rare condition called non-arteritic anterior ischemic optic neuropathy, or NAION, which can rapidly progress to blindness. Patient complaints and legal actions contend that popular weight-loss medications carry severe ocular risks that patients and physicians need to know before starting treatment.
The Anatomy of Sudden Vision Loss
Christmas Eve Warning Signs
Jay Vandergriff started taking Ozempic in 2023 and used the medication for a year before experiencing sudden vision changes just after Christmas 2024.
Vandergriff stated on “NewsNation Prime” that his symptoms did not develop gradually. He first noticed what looked like an eraser smear on his glasses, but realized the distortion was in his eye after cleaning the lenses.
Diagnosis and Daily Impact
He was subsequently diagnosed with NAION, a condition where blood flow to the optic nerve is blocked, causing vision loss that may quickly progress to blindness.
Vandergriff stated he was never warned that Ozempic could be associated with sudden vision loss, noting that he would have avoided the medication had he known. The vision loss has left him with roughly two-thirds of his sight impaired, creating daily challenges while traveling and moving through his surroundings with what he described as a dark curtain below his field of view.
Demanding Accountability and Routine Exams
Danielle Gold, an attorney representing Vandergriff, argues that the U.S. Food and Drug Administration should require GLP-1 drug manufacturers to update their warning labels to include NAION as a potential risk.
Gold stated that patients should be informed prior to starting the medication and can undergo a routine eye exam to determine if they possess an anatomical vulnerability known as a “disc at risk” that may predispose them to developing NAION.
The Push for Clearer Warnings
The lawsuits allege that manufacturers and regulators need to take accountability and properly compensate clients who have suffered life-changing injuries from the medications, maintaining that both patients and doctors deserve clear warnings about serious ocular risks before beginning treatment.